Form 8-K - Current report:
SEC Accession No. 0001193125-25-042785
Filing Date
2025-02-28
Accepted
2025-02-28 17:11:12
Documents
13
Period of Report
2025-02-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d924647d8k.htm   iXBRL 8-K 25736
  Complete submission text file 0001193125-25-042785.txt   148109

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA spro-20250225.xsd EX-101.SCH 2867
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20250225_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20250225_pre.xml EX-101.PRE 11272
16 EXTRACTED XBRL INSTANCE DOCUMENT d924647d8k_htm.xml XML 3677
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 25692054
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)